SXL
ATNM icon

Summit X LLC’s Actinium Pharmaceuticals ATNM Stock Holding History

Summit X LLC’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$24K Buy
2,273
+523
+30% +$3.96K 0.01% 203
2020
Q1 		$10K Buy
1,750
+167
+11% +$1.19K ﹤0.01% 191
2019
Q4 		$10K Buy
1,583
+416
+36% +$2.87K ﹤0.01% 234
2019
Q3 		$8K Hold
1,167
– – ﹤0.01% 228
2019
Q2 		$8K Hold
1,167
– – ﹤0.01% 234
2019
Q1 		$16K Hold
1,167
– – 0.01% 238
2018
Q4 		$14K Hold
1,167
– – 0.01% 201
2018
Q3 		$26K Buy
1,167
+84
+8% +$1.71K 0.01% 222
2018
Q2 		$21K Buy
+1,083
New +$13.7K 0.01% 206
2018
Q1 		– Sell
-367
Closed -$8K – 185
2017
Q4 		$8K Hold
367
– – 0.01% 178
2017
Q3 		$7K Hold
367
– – ﹤0.01% 180
2017
Q2 		$13K Buy
+367
New +$15.4K 0.01% 179

Other funds holding ATNM

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Summit X LLC's ATNM Position: Q2 2020 in Review

Summit X LLC increased its Actinium Pharmaceuticals (ATNM) stake by 30% in Q2 2020, buying an estimated $3.96K and bringing the position to 2,273 shares worth $24K. The position accounts for 0.01% of the portfolio, ranked #203.

Summit X LLC first reported a position in ATNM in Q2 2017 and has held it in 12 quarters since. The position peaked at $26K in Q3 2018. 59 funds tracked by Wall St. Rank hold ATNM as of Q2 2020.

  • Summit X LLC held 2,273 shares of Actinium Pharmaceuticals worth $24K as of Q2 2020.
  • Summit X LLC bought 523 Actinium Pharmaceuticals shares in Q2 2020, an estimated $3.96K.
  • Actinium Pharmaceuticals made up 0.01% of Summit X LLC's portfolio in Q2 2020, its #203 holding.
  • Summit X LLC first reported a position in Actinium Pharmaceuticals in Q2 2017 and has held it in 12 quarters since.
  • Summit X LLC's Actinium Pharmaceuticals position peaked at $26K in Q3 2018.
  • 59 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2020.

Based on Summit X LLC's 13F filing for Q2 2020, filed 13 Aug 2020.